单中心、随机、双盲、安慰剂对照设计评价重组呼吸道合胞病毒疫苗(CHO细胞)在18周岁及以上人群中接种的安全性、免疫原性的Ⅰ/II期临床试验
[Translation] A single-center, randomized, double-blind, placebo-controlled Phase I/II clinical trial to evaluate the safety and immunogenicity of a recombinant respiratory syncytial virus vaccine (CHO cells) in people aged 18 years and above
评价不同剂量重组呼吸道合胞病毒疫苗(CHO细胞)在18周岁及以上人群的安全性和免疫原性。
[Translation] To evaluate the safety and immunogenicity of different doses of recombinant respiratory syncytial virus vaccine (CHO cells) in people aged 18 years and above.
100 Clinical Results associated with Chengdu Huarenkang Biotechnology Co., Ltd.
0 Patents (Medical) associated with Chengdu Huarenkang Biotechnology Co., Ltd.
100 Deals associated with Chengdu Huarenkang Biotechnology Co., Ltd.
100 Translational Medicine associated with Chengdu Huarenkang Biotechnology Co., Ltd.